- Home
- MVSTW vs CMMB Comparison
MVSTW vs CMMB Comparison
Compare MVSTW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVSTW | CMMB |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Israel |
| Employees | 1921 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 13.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MVSTW | CMMB |
|---|---|---|
| Price | $0.02 | $1.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 119.5K | 69.4K |
| Earning Date | 03-14-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $370,989,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.75 |
| Revenue Growth | ★ 39.03 | N/A |
| 52 Week Low | $0.02 | $0.87 |
| 52 Week High | $0.65 | $3.86 |
Technical Indicators
Market Signals| Indicator | MVSTW | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 33.03 | 36.68 |
| Support Level | N/A | $0.88 |
| Resistance Level | $0.07 | $1.64 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 0.65 | 0.00 |
Price Performance
Historical ComparisonAbout MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.